Arizeke Pharmaceuticals Overview
- Founded
-
1997
- Status
-
Private
- Latest Deal Type
-
2ndary - Private
Arizeke Pharmaceuticals General Information
Description
Developer of technologies for oral delivery of macromolecules. The company's technology takes advantage of an active transport system, using the polymeric immunoglobulin receptor (pIgR) highly expressed in the intestinal and lung epithelium, and enables delivery of macromolecules such as therapeutic proteins and antibodies via oral or nasal administration.
Contact Information
Website
www.arizeke.com
Ownership Status
Privately Held (backing)
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Drug Delivery
Drug Discovery
Primary Office
- 6828 Nancy Ridge Drive
- San Diego, CA 92121
- United States
Arizeke Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Secondary Transaction - Private | 000.00 | Completed | ||||
| 2. Later Stage VC | 01-Jan-2004 | 000.00 | Completed | Generating Revenue | ||
| 1. Later Stage VC (Series C) | 01-May-2001 | $16.8M | $16.8M | Completed | Generating Revenue |
Arizeke Pharmaceuticals Patents
Arizeke Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20040157330-A1 | Cyclic polypeptide fusions for delivery of therapeutic, diagnostic, prophylactic or imaging molecules across polarized cells; drug delivery | Inactive | 09-Jan-2003 | 0000000000 | |
| AU-2004204763-A1 | Compositions and methods for targeted biological delivery of molecular carriers | Inactive | 09-Jan-2003 | 0000000000 | |
| CA-2512717-A1 | Compositions and methods for targeted biological delivery of molecular carriers | Inactive | 09-Jan-2003 | 0000000000 | |
| EP-1587524-A4 | Compositions and methods for targeted biological delivery of molecular carriers | Inactive | 09-Jan-2003 | 0000000000 | 0 |
| EP-1587524-A2 | Compositions and methods for targeted biological delivery of molecular carriers | Inactive | 09-Jan-2003 | C07K16/283 |